Ovagen caps #60

Indications

Metabolic disorders; reduced liver function; skin diseases; inflammatory liver diseases; viral hepatitis of all types.

Developed by the St. PETERSBURG Institute of Bioregulation and gerontology on the technology of patented Havinson.H. Peptide bioregulator of the liver.

Recommended

- with metabolic disorders
- with reduced liver function
- skin diseases
- to normalize lipid metabolism in atherosclerosis and obesity
- for the prevention of diabetes
- inflammatory diseases of the liver
- with the consequences of viral hepatitis of all types
- with alcoholic and toxic liver lesions
- in acute liver failure
- during the preoperative and postoperative periods in surgical interventions on the liver
- chronic liver failure
- with long-term antibiotic therapy
- during chemotherapy and radiation therapy
- with cholestasis, biliary dyskinesia
- cirrhosis of the liver of different Genesis
- in enteropathy, dyspepsia
- for the prevention of liver disease in the elderly and senile age.

Method of application

Adults take 1-2 capsules 1-2 times a day with meals. Duration of administration 10-30 days. It is advisable to repeat the course after 4-6 months.

During the clinical study of Ovagen, no side effects, complications and drug dependence were revealed.

Contraindications: individual intolerance of components, pregnancy, breast-feeding.

Store in a dry, dark place at room temperature.

Composition

Peptide complex as-3-(leucine, glutamic acid, aspartic acid). Excipients: microcrystalline cellulose (E460), beet sugar, lactose, starch, twin-80. As an additional source of peptides.

Contraindications

Individual intolerance of components, pregnancy, breast-feeding. It is recommended to consult a doctor before use.

Bioregulator normalization of liver and gastrointestinal tract

Ovagen is a peptide complex containing amino acids that contribute to the normalization of liver function and gastrointestinal tract.

The clinical study established the effectiveness of Ovagen in the comprehensive prevention and treatment of patients suffering from hepatitis of various etiologies, in the prevention of complications of radiation and chemotherapy and side effects when using antibiotics and other drugs, as well as the effects of exposure to various adverse factors (including environmental, toxic), malnutrition, as well as to maintain liver function in the elderly and senile age.

It is possible to use Ovagen to reduce withdrawal syndrome, increase appetite and performance.

Ovagen is recommended to take 1-2 capsules 1-2 times a day with meals. The length of treatment is 20-30 days. It is advisable to repeat the course after 4-6 months.

Experimental study of the biological properties of Ovagen in animals showed that its use improves not only individual indicators of cellular and tissue homeostasis in liver cells, but also normalizes the functions of the digestive system as a whole, disturbed as a result of stress, negative effects of adverse environmental factors, the development of age-related pathology. Currently, there is an increase in the number of patients with chronic liver lesions, which are common mainly in people of working age. Adverse social and environmental factors play a major role in increasing the incidence of disease.

The clinical study of Ovagen involved 106 patients with chronic hepatitis and cancer patients after chemotherapy, including 60 men and 46 women aged 35 to 68 years. The duration of the disease ranged from 3 to 10 years. Patients of the main group (68 people) in addition to conventional treatments received Ovagen 2 capsules 2 times a day with meals for 20 days. The control group consisted of 38 similar patients who were prescribed only conventional drugs.

Most patients complained of pain in the right hypochondrium, General weakness and fatigue, 73% of patients had dyspeptic disorders. In 53% of patients, hyperbilirubinemia, an increase in the level of alanine aminotransferase, an increase in the globulin fraction of blood proteins, mainly due to the fraction of immunoglobulins M, which indicates a certain activity of the chronic inflammatory process.

Patients ' complaints were subjectively assessed in dynamics. General clinical examination of blood and urine, biochemical and immunological examination of blood (determination of immunoglobulins by Mancini), ultrasound examination of the liver were performed.

After the application of Ovagen, most patients noted the disappearance of weakness, increased appetite and efficiency. The intensity of pain syndrome significantly decreased in 53% of patients.

Cancer patients subjectively noted improvement in health, reducing weakness, reducing the intensity of dyspeptic disorders.

Particular attention was paid to the evaluation of THE results of biochemical studies characterizing the aminotransferase activity, pigment and protein-forming functions of the liver. Objectively, most patients after the use of Ovagen showed stabilization of biochemical parameters: the level of bilirubin, alanine aminotransferase. The study of peripheral blood immunoglobulins, which are an essential criterion for the activity of the inflammatory process, after a course of application of Ovagen showed a significant decrease in the level of IgM.

Thus, the obtained results of clinical study testify to the hepatoprotective properties of Ovagen and the feasibility of its use in patients with acute and chronic forms of liver damage, cancer patients after radiation and chemotherapy, as well as for the prevention of various liver diseases and their complications.